secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2025-09-04T23:59:59+00:00
Accession:  0001671584-25-000005
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo expands oncology pipeline with two new trispecific candidates APVO452 and APVO451
--------------------------------------------------------------------------------

- Filed provisional patents for APVO452 (PSMA x CD3 x CD40) targeting prostate cancer and APVO451 (Nectin-4 x CD3 x CD40) for multiple solid tumors.
- Trispecific design engages tumor antigen, T cells, and immunosuppressive cells via ADAPTIR-FLEX platform to modulate tumor microenvironment.
- Mipletamig clinical validation: >100 patients treated with high remission rates and no observed cytokine release syndrome in frontline AML.
- Pipeline now includes 8 bispecific/trispecific candidates; 5 employ CRIS-7-derived CD3 binding domain for improved safety.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000167158425000005/0001671584-25-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000167158425000005/apvo-20250904.htm
  HTML page:      https://secwatch.observer/filing/0001671584-25-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer